Percutaneous Coronary Intervention

Data from a retrospective analysis show there are significant differences in the types of complex high-risk PCI cases undertaken across centers in England and Wales, as well as differences in clinical outcomes across age groups.

Patients undergoing coronary procedures who received care from a cardiologist using clinical decision support with audit and feedback were less likely to develop AKI compared with patients who received usual care, according to researchers.

After STEMI treated with primary PCI, men and women were equally likely to experience any MI, any revascularization or die of any cause during 10 years of follow-up, data from a retrospective analysis show.

Routine coronary angiography with revascularization when appropriate did not reduce 5-year mortality risk in patients with advanced chronic kidney disease and ischemia compared with an initial strategy of medical therapy.

In a meta-analysis of seven trials of patients who had coronary angiography with or without PCI, those who had transradial access had lower 30-day rates of mortality and major bleeding compared with those who had transfemoral access.

In adults with high bleeding risk, early deintensification of dual antiplatelet therapy after PCI was associated with less bleeding and no increased ischemic risk beyond 12 months vs. standard treatment, according to a speaker.

In patients with acute MI and multivessel CAD, a fractional flow reserve-guided PCI strategy for non-infarct-related artery lesions was superior to an angiography-guided PCI strategy, according to the results of the FRAME-AMI trial.

In patients with severe left ventricular systolic dysfunction on optimal medical therapy for HF, undergoing PCI did not improve rates of all-cause death or HF hospitalization, according to the results of the REVIVED-BCIS2 trial.

KOAG LLC, a Minneapolis-based medical device firm, announced it received FDA clearance for its topical vascular closure system.

Among patients undergoing high-risk PCI with mechanical circulatory support who survived to 90 days without further major cardiac complications, many had improved left ventricular ejection fraction, according to data from RESTORE EF.